GLP-1 for type 2 diabetes (Q33794098)

29 July 2017

1 reference

title

GLP-1 for type 2 diabetes (English)

1 reference

29 July 2017

1 reference

1

Bo Ahrén

1 reference

PubMed ID

21237153

29 July 2017

language of work or name

English

0 references

publication date

13 January 2011

1 reference

Experimental Cell Research

29 July 2017

1 reference

29 July 2017

317

1 reference

29 July 2017

9

1 reference

29 July 2017

1239-1245

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Mechanisms of action of glucagon-like peptide 1 in the pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

The role of GLP-1 in the life and death of pancreatic beta cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Alpha cell function in health and disease: influence of glucagon-like peptide-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Emerging treatment options for type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Association of pancreatitis with glucagon-like peptide-1 agonist use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.01.010

10.1016/J.YEXCR.2011.01.010

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

21237153